Table 4

Comparison of healthcare resource use related to ophthalmological diagnosis during the follow-up for patients with DME who received either anti-VEGF agents or a DEX-implant

Mean (±SD)P value
Anti-VEGFDEX-implantParametric*Non-parametric†
Optical coherence tomography7.09 (±3.38)7.43 (±3.15)0.23830.3623
Fluorescein angiography1.23 (±0.56)1.23 (±0.48)0.98520.6477
Fundus examination9.25 (±5.02)9.73 (±4.55)0.25350.1126
Fundus photography6.2 (±3.80)6.47 (±3.86)0.45710.4459
Tonometry12.08 (±6.09)13.21 (±7.09)0.05020.1191
Slit-lamp biomicroscopy12.4 (±6.01)13.15 (±6.61)0.18930.2375
Intravitreal injection2.69 (±2.29)2.089 (±1.37)0.0010.0044
  • Anti-VEGF includes ranibizumab and aflibercept.

  • *Estimated based on the t-test.

  • †Estimated based on the Wilcoxon test.

  • anti-VEGF, antivascular endothelial growth factor; DEX-implant, dexamethasone intravitreal implant; DME, diabetic macular oedema.